---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-127997"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-12-12T23:59:59+00:00"
generated_at: "2026-05-29T04:05:12.842845+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting

## Summary
- Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.
- Eliminated 'liberal' share recycling for stock options and SARs.
- Incentive stock option limit raised to 3,619,586 shares.
- David Domzalski and Patrick LePore re-elected as Class III directors.
- Baker Tilly ratified as auditor; say-on-pay approved; advisory vote set for every year.

## SEC filing metadata
- accession: 0001104659-24-127997
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465924127997/0001104659-24-127997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465924127997/tm2430841d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-127997
- JSON: https://secwatch.observer/filing/0001104659-24-127997.json
- Plain text: https://secwatch.observer/filing/0001104659-24-127997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.